Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Supplementary MedlinePlus references to lung cancer and genetics are no longer shown alongside the study’s resource links.
    Difference
    0.2%
    Check dated 2026-11-16T14:21:22.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The study record for the pembrolizumab re-challenge trial is displayed, including its completed status, study details, eligibility criteria, locations, design, and outcome measures.
    Difference
    56%
    Check dated 2026-11-09T13:58:23.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The site revision in the footer updates from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T15:46:15.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    A site-wide notice links to updates and FAQs about NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology under Executive Order 14434.
    Difference
    1%
    Check dated 2026-10-26T16:46:57.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The footer now displays site revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-19T21:59:28.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The site revision label changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-13T04:26:45.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.